Most recent by Jame Abraham, MD, FACP
Medicaid expansion under ACA appears to improve cancer clinical trial access
CHICAGO — The Affordable Care Act’s expansion of Medicaid resulted in a nearly threefold increase in the percentage of patients using Medicaid in cancer trials by early 2020, according to study results presented during ASCO Annual Meeting.
VIDEO: Radiation, trastuzumab combination ‘not recommended’ for HER2+ DCIS
In this video, Jame Abraham, MD, director of breast oncology at Cleveland Clinic, highlighted the results from the NSABP B-43 trial that included radiation therapy efficacy with or without trastuzumab in women with ductal carcinoma in situ who have undergone lumpectomy.
VIDEO: Investigational antibody-drug conjugate shows promise in breast cancer
In this video, Jame Abraham, MD, director of breast oncology at Cleveland Clinic, spoke about the phase 1 study of the investigational antibody-drug conjugate SGN-LIV1A (Seattle Genetics) for metastatic breast cancer, presented at ASCO20Virtual Scientific Program.
Neoadjuvant pembrolizumab benefits patients with high-risk triple-negative breast cancer
SAN ANTONIO — The addition of pembrolizumab to neoadjuvant chemotherapy and as adjuvant therapy increased pathologic complete response among patients with high-risk disease, according to results of the KEYNOTE-522 trial presented at San Antonio Breast Cancer Symposium.
Treatment options for HER2-positive breast cancer vary by disease stage
Jame Abraham, MD, is the director of the breast oncology program at Cleveland Clinic. Abraham spoke with Healio about current treatment options for HER2-positive breast cancer, as well as important ongoing and planned trials that may impact management of the disease.
Extended adjuvant therapy fails to improve outcomes in hormone receptor-positive breast cancer
SAN ANTONIO — Postmenopausal women with hormone receptor-positive breast cancer who underwent 5 additional years of extended anastrozole therapy received no additional benefit compared with women who underwent 2 additional years of therapy, according to data from the ABCSG-16 phase 3 trial presented at the San Antonio Breast Cancer Symposium.
VIDEO: Additional research necessary to define role of PARP inhibitors for BRCA–mutated breast cancer
SAN ANTONIO — Jame Abraham, MD, director of the breast oncology program at Cleveland Clinic, offers perspective on the BROCADE study results presented at the San Antonio Breast Cancer Symposium.
VIDEO: Scalp-cooling device reduces chemotherapy-associated hair loss
SAN ANTONIO — A scalp-cooling system helped minimize hair loss among patients with breast cancer who underwent chemotherapy, according to study results presented at San Antonio Breast Cancer Symposium.